Barry A. Bunin, Ph.D. is the CEO & President of Collaborative Drug Discovery. Dr. Bunin has overseen scalable, consistent growth over the last two decades. CDD is hosting the most private drug discovery data in a single database in the world for the range of experiments run by biologists and chemists. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly & Co. Dr. Bunin is on a patent for Kyprolis™ (Carfilzomib for Injection) — a selective proteasome inhibitor that received accelerated FDA approval for the treatment of patients with multiple myeloma that was widely viewed as the centerpiece of Amgen’s $10.4 Billion acquisition of Onyx Pharmaceuticals. Dr. Bunin co-authored two books including the textbook for high throughput synthesis "The Combinatorial Index", as well as "Chemoinformatics: Theory, Practice, Products". Dr. Bunin was a Medicinal Chemist at Axys Pharmaceuticals and Genentech, received his BA from Columbia University and PhD at UC Berkeley with Professor Jonathan Ellman where they synthesized and screened the first libraries in the billion dollar field of modern high throughput, small molecule synthesis.

‍